Welcome to our dedicated page for Chromadex news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on Chromadex stock.
ChromaDex Corp. (NASDAQ: CDXC), transitioning to the name Niagen Bioscience, Inc. with a new Nasdaq ticker symbol NAGE, generates a steady flow of news centered on NAD+ science and healthy aging. As the self-described global authority on nicotinamide adenine dinucleotide (NAD+), the company regularly issues updates on its Niagen ingredient, Tru Niagen supplement brand, and pharmaceutical-grade Niagen IV and injection products.
News for CDXC often includes financial results and outlooks, where ChromaDex reports quarterly and annual net sales, gross margins, net income, and cash flow metrics, along with commentary on trends in Tru Niagen and Niagen ingredient sales. These releases may also discuss expectations for future revenue growth, margin performance, and planned investments in research, development, and marketing.
Investors can also expect corporate and investor relations announcements, such as participation in healthcare and growth company conferences, investor summits, and panel discussions on longevity and supplementation. These events typically feature company management presenting ChromaDex’s strategy, financial performance, and updates on its NAD+ research and product pipeline.
Another key category of news involves product and partnership developments. ChromaDex has announced the expansion of Niagen IV and related pharmaceutical-grade Niagen products across wellness clinic networks, as well as collaborations where Niagen serves as a hero ingredient in third‑party longevity supplements. The company also highlights recognition in industry lists and awards related to health products and business impact.
Finally, ChromaDex issues scientific and regulatory updates, including information about FDA designations for nicotinamide riboside in rare disease indications and progress toward regulatory milestones. For anyone tracking CDXC, or its successor symbol NAGE, this news feed offers a consolidated view of the company’s financial performance, clinical and regulatory progress, commercial expansion, and branding evolution around Niagen and NAD+ science.
ChromaDex Corp. (NASDAQ:CDXC), a company focused on NAD+ and healthy aging science, has announced a significant corporate rebranding initiative. The company will change its name to Niagen Bioscience, Inc. and adopt a new ticker symbol 'NAGE' on the Nasdaq, effective March 19, 2025.
The transition requires no action from current shareholders, and the company's CUSIP number will remain unchanged. ChromaDex plans to release additional information about the name change, rebranding, and future initiatives in a subsequent announcement.
ChromaDex (NASDAQ: CDXC), a leader in NAD+ science and healthy aging, has announced its participation in the 37th Annual ROTH Conference. CEO Rob Fried will be featured on the Longevity and Supplementation Panel on Monday, March 17, at 12:00 PM PT.
The conference will include various engagement formats such as one-on-one meetings, analyst-selected fireside chats, and industry panels. Both CEO Rob Fried and CFO Ozan Pamir will conduct in-person meetings with institutional investors during the event.
The conference will showcase approximately 450 private and public companies across multiple growth sectors, including Healthcare, Technology, Business Services, Consumer, Industrial Growth, Sustainability, and more. The Longevity and Supplementation Panel will be accessible via livestream at wsw.com/webcast/roth50.
ChromaDex (NASDAQ:CDXC) reported strong financial results for Q4 and full year 2024. Fourth quarter highlights include net sales of $29.1 million (up 37% YoY), with Tru Niagen® sales of $22.7 million (up 29% YoY), and net income of $7.2 million.
Full year 2024 performance showed total net sales of $99.6 million (up 19% YoY), gross margin of 61.8%, and net income of $8.6 million. The company generated $12.1 million in operating cash flows and ended the year with $44.7 million in cash and no debt.
Key developments include the launch of Niagen Plus, a pharmaceutical-grade product line available at over 475 U.S. wellness clinics, and receiving FDA Orphan Drug and Rare Pediatric Disease Designations. For 2025, ChromaDex projects approximately 18% year-over-year revenue growth.
ChromaDex (NASDAQ:CDXC), a leader in NAD+ research focusing on healthy aging, has scheduled its Fourth Quarter and Fiscal Year 2024 financial results conference call for March 4, 2025, at 4:30 p.m. ET. The financial results will be released after market close on the same day.
The company will host an investor conference call to discuss Q4 and FY2024 results, providing a general business update. Participants are advised to join 10 minutes before the call using the toll-free number 888.596.4144 with Conference ID 8584242. A webcast replay will be available until March 11, 2025.
ChromaDex Corp. (NASDAQ: CDXC), a leader in NAD+ research and healthy aging science, has announced its participation in the upcoming Lytham Partners 2025 Investor Healthcare Summit. The virtual event will feature a company presentation scheduled for Monday, January 13, 2025, at 12:00 p.m. ET.
Investors can access the webcast directly through Lytham Partners' dedicated event page or the conference homepage. A replay option will be available following the presentation. Additionally, one-on-one investor meetings can be arranged through Lytham representatives or by contacting Ben Shamsian, Vice President at Lytham Partners, who serves as ChromaDex's investor relations contact.
ChromaDex Corp. (NASDAQ:CDXC) has been named to the Inc. 2024 Best in Business list in the Health Products category, recognizing its contributions to the industry through NAD+ research and healthy aging products. The company's portfolio includes Tru Niagen®, a dietary supplement, and the new Niagen IV, both featuring patented nicotinamide riboside (NR), their high-quality NAD+ precursor. This recognition by Inc. magazine acknowledges companies that have achieved significant milestones and demonstrated exceptional execution in their core business.
ChromaDex Corp. (NASDAQ: CDXC) announces that its patented nicotinamide riboside (NR) ingredient, Niagen®, has been selected as the key ingredient in Longevity.Technology's new supplement. Niagen, recognized as the gold standard for NAD+ supplementation, is backed by over 30 peer-reviewed human clinical studies showing benefits in cellular, brain, heart, and muscle health. The company's intellectual property portfolio includes 90+ owned and licensed patents. Niagen is available through business partnerships and is the active ingredient in ChromaDex's Tru Niagen brand, currently the leading healthy-aging NAD+ supplement in the United States.
ChromaDex Corp. (NASDAQ:CDXC) has announced the nationwide rollout of its Niagen® IV products at over 200 Restore Hyper Wellness locations across the United States. Niagen IV, a pharmaceutical-grade nicotinamide riboside chloride (NRC) product, represents an advancement in NAD+ therapy, offering superior benefits compared to traditional NAD+ IV treatments. In clinical studies, Niagen IV demonstrated a 75% shorter infusion time, better tolerability, and achieved a 20% increase in whole blood NAD+ levels three hours post-infusion. The product is compounded and distributed by Wells Pharma of Houston, an FDA-registered 503B facility, and is available exclusively for clinics with medical clearance.
ChromaDex (NASDAQ:CDXC) reported strong Q3 2024 financial results with total net sales of $25.6 million, up 31% year-over-year. The company achieved record net income of $1.9 million ($0.02 per share) and Adjusted EBITDA of $2.9 million. Tru Niagen® sales reached $18.1 million, while Niagen® ingredient sales surged 368% to $6.7 million. Gross margin improved to 63.5%. The company expanded its Niagen+ product line to over 100 wellness clinics and expects approximately 15% revenue growth for full-year 2024.
ChromaDex Corp. (NASDAQ: CDXC) has rescheduled its third quarter 2024 financial results conference call to Thursday, October 31, 2024, at 4:30 p.m. ET. The company, which specializes in NAD+ research and healthy aging, will release its financial results for the quarter ended September 30, 2024, after market close on the same day. The conference call will include management discussion and a general business update. A replay of the call will be available until November 13, 2024.
FAQ
What is the current stock price of Chromadex (CDXC)?
What is the market cap of Chromadex (CDXC)?
